Beijing Tong Ren Tang Chinese Medicine Future Growth
Future criteria checks 3/6
Beijing Tong Ren Tang Chinese Medicine is forecast to grow earnings and revenue by 16.5% and 14.8% per annum respectively. EPS is expected to grow by 16.5% per annum. Return on equity is forecast to be 15.7% in 3 years.
Key information
16.5%
Earnings growth rate
16.5%
EPS growth rate
| Pharmaceuticals earnings growth | 11.7% |
| Revenue growth rate | 14.8% |
| Future return on equity | 15.7% |
| Analyst coverage | Low |
| Last updated | 11 Sep 2024 |
Recent future growth updates
Recent updates
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up
Oct 04
Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders
Sep 06Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?
Sep 02Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk
Feb 05Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Jan 03A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Sep 28Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today
Jul 12Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?
Mar 29Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28
Apr 28Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28
Mar 25Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?
Oct 27Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 28Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Mar 11What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Feb 04Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?
Jan 18
Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?
Dec 29Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Dec 11Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,011 | 738 | N/A | N/A | 1 |
| 12/31/2025 | 1,850 | 671 | N/A | 657 | 2 |
| 12/31/2024 | 1,628 | 559 | N/A | 681 | 2 |
| 6/30/2024 | 1,377 | 494 | -384 | -358 | N/A |
| 3/31/2024 | 1,451 | 517 | 28 | 52 | N/A |
| 12/31/2023 | 1,525 | 540 | 439 | 461 | N/A |
| 9/30/2023 | 1,721 | 619 | 552 | 584 | N/A |
| 6/30/2023 | 1,918 | 697 | 665 | 706 | N/A |
| 3/31/2023 | 1,824 | 672 | 587 | 627 | N/A |
| 12/31/2022 | 1,731 | 646 | 509 | 547 | N/A |
| 9/30/2022 | 1,605 | 601 | 636 | 665 | N/A |
| 6/30/2022 | 1,478 | 555 | 763 | 782 | N/A |
| 3/31/2022 | 1,517 | 582 | 758 | 779 | N/A |
| 12/31/2021 | 1,556 | 608 | 754 | 777 | N/A |
| 9/30/2021 | 1,504 | 595 | 575 | 596 | N/A |
| 6/30/2021 | 1,452 | 583 | 397 | 414 | N/A |
| 3/31/2021 | 1,384 | 563 | 250 | 265 | N/A |
| 12/31/2020 | 1,315 | 542 | 103 | 116 | N/A |
| 9/30/2020 | 1,246 | 483 | 198 | 213 | N/A |
| 6/30/2020 | 1,178 | 424 | 294 | 310 | N/A |
| 3/31/2020 | 1,305 | 490 | 414 | 430 | N/A |
| 12/31/2019 | 1,433 | 556 | 534 | 551 | N/A |
| 9/30/2019 | 1,505 | 594 | 553 | 568 | N/A |
| 6/30/2019 | 1,577 | 632 | 572 | 585 | N/A |
| 3/31/2019 | 1,546 | 601 | N/A | N/A | N/A |
| 12/31/2018 | 1,514 | 581 | 524 | 578 | N/A |
| 9/30/2018 | 1,466 | 552 | N/A | N/A | N/A |
| 6/30/2018 | 1,402 | 540 | 447 | 507 | N/A |
| 3/31/2018 | 1,330 | 516 | N/A | N/A | N/A |
| 12/31/2017 | 1,266 | 490 | N/A | 469 | N/A |
| 9/30/2017 | 1,212 | 469 | N/A | N/A | N/A |
| 6/30/2017 | 1,166 | 449 | N/A | 465 | N/A |
| 3/31/2017 | 1,134 | 444 | N/A | N/A | N/A |
| 12/31/2016 | 1,084 | 420 | N/A | 468 | N/A |
| 9/30/2016 | 1,063 | 431 | N/A | N/A | N/A |
| 6/30/2016 | 1,028 | 410 | N/A | 415 | N/A |
| 3/31/2016 | 1,002 | 380 | N/A | N/A | N/A |
| 12/31/2015 | 970 | 354 | N/A | 354 | N/A |
| 9/30/2015 | 939 | 337 | N/A | N/A | N/A |
| 6/30/2015 | 881 | 320 | N/A | 316 | N/A |
| 3/31/2015 | 834 | 304 | N/A | N/A | N/A |
| 12/31/2014 | 761 | 287 | N/A | 245 | N/A |
| 9/30/2014 | 733 | 286 | N/A | N/A | N/A |
| 6/30/2014 | 699 | 267 | N/A | 202 | N/A |
| 3/31/2014 | 652 | 249 | N/A | N/A | N/A |
| 12/31/2013 | 614 | 220 | N/A | 143 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3613's forecast earnings growth (16.5% per year) is above the savings rate (2.3%).
Earnings vs Market: 3613's earnings (16.5% per year) are forecast to grow faster than the Hong Kong market (11.5% per year).
High Growth Earnings: 3613's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3613's revenue (14.8% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 3613's revenue (14.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3613's Return on Equity is forecast to be low in 3 years time (15.7%).